Werfen completed the acquisition of Immucor from TPG for $2bn.

Werfen, a developer, manufacturer and distributor of Specialized Diagnostic instruments, related reagents, automation workcells, and data management solutions, completed the acquisition of Immucor, a provider of transfusion and transplantation diagnostic products, from TPG, an alternative asset management firm, for $2bn. "As a global leader in the research, development, manufacturing and distribution of innovative, Specialized Diagnostics solutions for hospitals and clinical laboratories, Immucor is a natural fit with our existing business model. We highly value Immucor's commitment to enhancing care for all patients in need of a transfusion or transplant. This fits squarely with our long-term vision and strategy, aligns with our focus, and complements Werfen's values," Marc Rubiralta, Werfen President.